[Alice: Clinical trial application for AST1001 for injection was approved by the FDA] On October 23, Ellis (688578.SH) announced that the company recently received a letter from the U.S. Food and Drug Administration (FDA) agreeing to conduct a clinical trial of AST1001 for injection for the treatment of adult patients with locally advanced or metastatic solid tumors who have failed standard treatments in the past. This drug is an antibody-conjugated drug independently developed by the company. It is composed of a bispecific antibody targeting EGFR and c-MET coupled with a topoisomerase I inhibitor payload-linker. This approval is a phased achievement of the company's new drug research and development and will not have a significant impact on recent performance.